

February, 05, 2024

Andrzej S Tarnawski, DSc, MD, PhD,
Editor-in-Chief
World Journal of Gastroenterology

Dear Editor:

We wish to re-submit the manuscript titled “MicroRNA in Inflammatory Bowel Disease: what do we know and what can we expect?”. The manuscript ID is 92273.

We thank you and the reviewers for your thoughtful suggestions and insights. The manuscript has benefited from these insightful suggestions. I look forward to working with you and the reviewers to move this manuscript closer to publication in the *World Journal of Gastroenterology*.

The manuscript has been rechecked and the necessary changes have been made in accordance with the reviewers' suggestions and in accordance with the journal's standards. The responses to all comments have been prepared and attached herewith. The manuscript was also revised in English and the revision certificate is also attached to this document. We also inform that figure 1 of the manuscript was created with the Biorender software (<https://www.biorender.com>), which is cited in section "Conflicts of Interest" and the license to publish the figure is attached herewith.

Thank you for your consideration. I look forward to hearing from you.

Sincerely,

Lígia Yukie Sasaki, MD, PhD
Assistant Professor, Department of Internal Medicine, São Paulo State University (Unesp),
Medical School, s/n. Bairro Rubião Junior, Botucatu
18618-686, São Paulo State, Brazil
Email: ligia.sasaki@unesp.br

Response to Reviewer 1 comments

Point 1: 4. Core tip. Please rephrase the Core Tip so it would be significantly different from the Abstract, especially LINES 85-88.

Response 1: We thank you for the very relevant observation. We carefully reformulated the Core Tip and we hope to have fully complied with the suggestion made.

Point 2: 6. Conclusions. - Well drafted and they are fully supported by the data presented in the paper - Please move Table 2 within the limits of the previous subsection “What can we expect from miRNAs in IBD”

Response 2: We thank you again for the pertinent observation and as suggested we moved table 2 to section “What can we expect from miRNAs in IBD”. However, to make this change it was necessary to reverse the order of the tables, so table 1 became called table 2 and table 2 became called table 1.

Response to Reviewers 2 comments

Point 1: What are the original findings of this manuscript? What are the new concepts that this study proposes? What are the future directions of the topic described in this manuscript?

Response 1: We thank you for the observation, we would like to clarify that the submitted proposal is an editorial, though. Once we know that miRNAs can be potential therapeutic targets or products for the development of new drugs for patients with IBD, the aim of the editorial was not to propose new concepts, but rather to explore the main findings and future perspectives regarding miRNAs and their roles in IBD in light of already published studies. In the second part of this editorial (WHAT CAN WE EXPECT FROM miRNAs IN IBD?), we tried to explore future applications of miRNAs in IBD in the clinical practice, such as diagnosis or biomarker of response, as pointed out in the article, showing the most recent articles in the literature. We hope that this editorial draws attention to the importance that genetic markers such as miRNAs have gained in recent years. We will soon have the possibility of using these biomarkers in clinical practice to

better monitor patients with chronic diseases, such as IBD. Some information was added in the manuscript to clarify this idea.

Response to Science editor comments

Point 1: The conclusion of the manuscript needs to make some minor changes before considering publication.

Response: We thank you for the observation. We have formulated the Conclusion.

Point 2: The English-language grammatical presentation needs to be improved to a certain extent.

Response: We thank you for the observation. The article was sent to English review.